News Markets & Companies
Synthomer to divest William Blythe for approximately EUR 35 million
Synthomer is selling its inorganic chemistry business William Blythe to the company’s management team and private equity firm H2 Equity Partners. The deal is expected to close by the end of May 2025.
On 6 May 2025, UK-based chemicals group Synthomer announced the divestment of William Blythe Limited, its inorganic chemistry subsidiary, to the company’s management team supported by H2 Equity Partners. The purchase price is GBP 30 million, equivalent to around EUR 35 million. Headquartered in Accrington, Lancashire, the business employs approximately 85 people and was previously part of Synthomer’s Health & Protection and Performance Materials division.
Founded in 1845, William Blythe specialises in developing and manufacturing inorganic derivatives based on elements such as tin, iodine, copper, zinc and tungsten. Its products are used in demanding applications across industries including life sciences, performance coatings, polymers, electronics, catalysis and renewable energy. In the financial year ending 31 December 2024, the company generated sales of GBP 54 million and stand-alone adjusted EBITDA of GBP 4 million.
Portfolio streamlining and debt reduction
The sale is part of Synthomer’s strategic review initiated in October 2022. CEO Michael Willome stated that while William Blythe has delivered strong performance over many years, the business offers limited synergies with the rest of the Group. Divesting it will simplify Synthomer’s site portfolio and sharpen its focus on higher-value, higher-growth speciality chemicals markets.
The transaction is subject to customary closing conditions and is expected to be completed by the end of May 2025. Net proceeds will be used to reduce the Group’s net debt.
